Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Evaluation of systemic exposure of nanoparticle suspensions subcutaneously administered to mice regarding stabilization, volume, location, concentration and size.

Sigfridsson K, Palmer M.

Drug Dev Ind Pharm. 2014 Oct;40(10):1318-24. doi: 10.3109/03639045.2013.817418. Epub 2013 Jul 23.

PMID:
23879245
3.

Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.

Yang H, Teng F, Wang P, Tian B, Lin X, Hu X, Zhang L, Zhang K, Zhang Y, Tang X.

Int J Pharm. 2014 Dec 30;477(1-2):88-95. doi: 10.1016/j.ijpharm.2014.10.025. Epub 2014 Oct 14.

PMID:
25455766
4.

Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth.

Ghosh I, Bose S, Vippagunta R, Harmon F.

Int J Pharm. 2011 May 16;409(1-2):260-8. doi: 10.1016/j.ijpharm.2011.02.051. Epub 2011 Mar 1.

PMID:
21371540
5.

Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.

Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le Lamer S, Amighi K.

Eur J Pharm Biopharm. 2006 Nov;64(3):360-8. Epub 2006 Jul 18.

PMID:
16846725
6.

Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.

Rao MR, Bajaj A.

Drug Res (Stuttg). 2014 Dec;64(12):663-7. doi: 10.1055/s-0034-1368701. Epub 2014 Feb 18.

PMID:
24549965
7.

Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies.

Parveen R, Ahmad FJ, Iqbal Z, Samim M, Ahmad S.

Drug Dev Ind Pharm. 2014 Sep;40(9):1206-12. doi: 10.3109/03639045.2013.810636. Epub 2013 Jul 4.

PMID:
23826860
8.

In vitro-in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps.

Hill A, Geissler S, Meyring M, Hecht S, Weigandt M, M├Ąder K.

Int J Pharm. 2013 Jul 15;451(1-2):57-66. doi: 10.1016/j.ijpharm.2013.04.060. Epub 2013 Apr 26.

PMID:
23628403
9.

Preparation of griseofulvin nanoparticle suspension by high-pressure homogenization and preservation of the suspension with saccharides and sugar alcohols.

Kamiya S, Kurita T, Miyagishima A, Arakawa M.

Drug Dev Ind Pharm. 2009 Aug;35(8):1022-8. doi: 10.1080/03639040802698786.

PMID:
19466885
10.

Food proteins as novel nanosuspension stabilizers for poorly water-soluble drugs.

He W, Lu Y, Qi J, Chen L, Hu F, Wu W.

Int J Pharm. 2013 Jan 30;441(1-2):269-78. doi: 10.1016/j.ijpharm.2012.11.033. Epub 2012 Nov 27.

PMID:
23194889
11.

Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with beta-cyclodextrin.

Nakate T, Yoshida H, Ohike A, Tokunaga Y, Ibuki R, Kawashima Y.

Eur J Pharm Biopharm. 2003 Mar;55(2):147-54.

PMID:
12637090
12.

Role of lipid-based excipients and their composition on the bioavailability of antiretroviral self-emulsifying formulations.

Chudasama A, Patel V, Nivsarkar M, Vasu K, Shishoo C.

Drug Deliv. 2015;22(4):531-40. doi: 10.3109/10717544.2014.891270. Epub 2014 Mar 7.

PMID:
24601856
13.

Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications.

Deng Z, Xu S, Li S.

Int J Pharm. 2008 Mar 3;351(1-2):236-43. Epub 2007 Oct 10.

PMID:
18093763
14.

Combining inkjet printing and amorphous nanonization to prepare personalized dosage forms of poorly-soluble drugs.

Cheow WS, Kiew TY, Hadinoto K.

Eur J Pharm Biopharm. 2015 Oct;96:314-21. doi: 10.1016/j.ejpb.2015.08.012. Epub 2015 Aug 29.

PMID:
26325060
15.

Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.

Sigfridsson K, Lundqvist AJ, Strimfors M.

Drug Dev Ind Pharm. 2009 Dec;35(12):1479-86. doi: 10.3109/03639040903025855.

PMID:
19929207
16.

Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.

Li F, Song S, Guo Y, Zhao Q, Zhang X, Pan W, Yang X.

Drug Deliv. 2015;22(4):487-98. doi: 10.3109/10717544.2014.885615. Epub 2014 Feb 13.

PMID:
24524289
17.

Development and characterization of an orodispersible film containing drug nanoparticles.

Shen BD, Shen CY, Yuan XD, Bai JX, Lv QY, Xu H, Dai L, Yu C, Han J, Yuan HL.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1348-56. doi: 10.1016/j.ejpb.2013.09.019. Epub 2013 Oct 5.

PMID:
24103635
18.

Lipoic acid nanoparticles: effect of polymeric stabilizer on appetite suppression.

Park CH, Lee KU, Park JY, Koh EH, Kim HS, Lee J.

Pharmazie. 2010 Aug;65(8):580-4.

PMID:
20824957
19.

Process parameter dependent growth phenomena of naproxen nanosuspension manufactured by wet media milling.

Bitterlich A, Laabs C, Krautstrunk I, Dengler M, Juhnke M, Grandeury A, Bunjes H, Kwade A.

Eur J Pharm Biopharm. 2015 May;92:171-9. doi: 10.1016/j.ejpb.2015.02.031. Epub 2015 Mar 9.

PMID:
25766272
20.

Application of co-grinding to formulate a model pMDI suspension.

Williams RO 3rd, Repka MA, Barron MK.

Eur J Pharm Biopharm. 1999 Sep;48(2):131-40.

PMID:
10469931

Supplemental Content

Support Center